查看购物车
  • Traditional Chinese
  • English
抗体药物偶联物市场规模及预测 2021-2031、全球及地区份额、趋势及成长机会分析报告涵盖范围：按技术、应用、目标、配销通路和地理划分
市场调查报告书
商品编码
1646513

抗体药物偶联物市场规模及预测 2021-2031、全球及地区份额、趋势及成长机会分析报告涵盖范围：按技术、应用、目标、配销通路和地理划分

Antibody Drug Conjugates Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Target, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 286 Pages | 订单完成后即时交付

价格

抗体药物偶联物市场规模预计将从 2023 年的 81 亿美元增至 2031 年的 380.7 亿美元；预计 2023 年至 2031 年期间市场复合年增长率为 21.3%。推动市场成长的主要因素包括主要参与者的策略性投资和核准产品供应的增加。此外，在预测期内，新适应症的扩展可能会促进市场发展。然而，製造方面的挑战是市场阻碍因素之一。

抗体-药物偶联物（抗体-药物偶联物）市场主要参与者之间的合併、收购、伙伴关係和合作等策略投资对其成长和发展有重大影响。这些策略使公司能够汇集资源、共享专业知识并利用互补优势来增强其在快速变化的环境中竞争优势。在寻求创新癌症疗法的过程中，抗体-药物偶联物因其能够选择性地靶向和破坏癌细胞，同时保护健康组织，从而最大限度地减少副作用的能力而受到关注。因此，大型製药和生物技术公司越来越多地建立策略联盟，以加速抗体-药物偶联物的开发和商业化。

随着市场竞争日益激烈，各公司寻求收购或合併其他拥有有前景的抗体药物偶联技术或候选药物的公司。例如，大型製药公司收购专门从事抗体药物偶联物开发的小型生技公司，以便将先进技术快速融入其现有产品线。此类收购有助于收购公司增强其产品组合，并获得可提高其治疗功效和安全性的新型连接技术、有效载荷和标靶机制。 2024 年 10 月，GlycoMimetics, Inc. 与 Crescent Biopharma, Inc. 达成收购协议，后者是一家私营生物技术公司，正在推动用于治疗实体肿瘤的肿瘤治疗药物研发。交易完成后，该公司计划以Crescent Biopharma, Inc. 的名义运作。设计和开发下一代抗体-药物偶联物。 2024 年 9 月，致力于开发下一代抗体药物偶联物的瑞士肿瘤学和生物技术公司 Araris Biotech AG 宣布与 Innate Pharma 达成协议。根据协议，Innate 将向 Araris 转让与其转谷氨酰胺酶结合技术相关的专利组合。

抗体-药物偶联物市场的竞争格局特征是主要参与者积极参与策略投资。这种活力鼓励企业创新和改进，努力实现产品差异化并在市场上确立领导地位。资本涌入肿瘤学领域吸引了新进入者，从而形成了一个更活跃的生态系统，鼓励创新想法。透过合併、收购、合作伙伴关係和合作进行的策略性投资在推动抗体-药物偶联物市场的成长方面发挥关键作用。这些投资透过增强产品组合、改进製造流程和促进创新来创造协同环境，以推动有效和有针对性的癌症治疗方法的发展。

比较公司分析根据产品组合（产品满意度、产品特性和可用性）、近期市场发展（併购、新产品发布和增强、投资和融资、奖励、协议、合作）对抗体药物偶联物市场进行评估和分类、合作伙伴关係、认可和扩张）以及地理存在，有助于更好地决策和了解竞争格局。该报告深入探讨了全球抗体药物偶联物市场领先供应商的最新重要发展和创新。主要市场参与者包括ADC Therapeutics SA、辉瑞公司、罗氏公司、第一三共株式会社、葛兰素史克公司、吉利德科学公司、阿斯特捷利康公司、安斯泰来製药公司、RemeGen 有限公司、武田製药有限公司、默克集团、强生公司、百时美施贵宝公司、BioNTech SE、艾伯维公司。

根据技术，抗体药物偶联物市场分为可裂解接头和不可裂解接头。 2023 年，可裂解连接体占据了市场的最大份额。根据应用，抗体药物偶联物市场分为血癌、脑癌、乳癌、卵巢癌、肺癌等。 2023 年，乳癌领域占据了最大的市场。

抗体药物偶联物市场的公司采用了各种有机和无机策略。有机策略主要包括产品发布和产品批准。市场上见证的无机成长策略是收购、合作和伙伴关係。这些成长策略使市场参与者能够扩大业务、增强地理影响力，同时促进整体市场的成长。此外，收购和合作等策略有助于加强他们的客户群并扩展他们的产品组合。以下列出了抗体药物偶联物市场主要参与者的一些重要发展。

2024年11月，阿斯特捷利康在新加坡建造了一座价值15亿美元的抗体药物偶联物（ADC）生产工厂，将改善其ADC产品组合的全球供应。 ADC 是一种先进的治疗方法，旨在利用标靶抗体将强效抗癌剂直接输送到癌细胞。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 发育基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：抗体药物偶联物市场格局

  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表
    • 核准产品清单
    • 管道分析
    • 监管指南

第 5 章：抗体药物偶联物市场 - 关键市场动态

  • 抗体药物偶联物市场 - 关键市场动态
  • 市场驱动因素
    • 关键参与者的策略投资
    • 增加核准产品的供应量
  • 市场限制
    • 製造挑战
  • 市场机会
    • 拓展新适应症
  • 未来趋势
    • 扩大临床试验管道
  • 驱动因素和限制因素的影响：

第 6 章：抗体药物偶联物市场 - 全球市场分析

  • 抗体药物偶联物市场收入，2021-2031 年
  • 概述
  • 抗体药物偶联物市场预测分析

第 7 章：抗体药物偶联物市场分析 - 依技术

  • 可裂解接头
  • 不可切割接头

第 8 章：抗体药物偶联物市场分析 - 按应用

  • 血癌
  • 脑癌
  • 乳癌
  • 卵巢癌
  • 肺癌
  • 其他的

第 9 章：抗体药物偶联物市场分析 - 按目标

  • HER2
  • CD22
  • CD30
  • 其他的

第 10 章：抗体药物偶联物市场分析 - 按配销通路

  • 零售药局
  • 医院药房
  • 网路药局

第 11 章：抗体药物偶联物市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：竞争格局

    • 热图分析
    • 公司股票分析：

第 13 章：产业格局

  • 概述
  • 抗体药物偶联物市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 14 章：公司简介

  • ADC Therapeutics SA
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Daiichi Sankyo Co Ltd
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Merck KGaA
  • Johnson & Johnson
  • Bristol-Myers Squibb Co
  • BioNTech SE
  • AbbVie Inc

第 15 章：附录

Product Code: TIPRE00003494

The antibody drug conjugates market is expected to reach US$ 38.07 billion by 2031 from US$ 8.10 billion in 2023; the market is estimated to grow at a CAGR of 21.3% during 2023-2031. Major factors driving the market growth include strategic investments by key players and increase in availability of approved products. Further, expansion into new indications is likely to boost the market during the forecast period. However, manufacturing challenges are among the market deterrents.

Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the antibody-drug conjugates (antibody-drug conjugates) market significantly influence its growth and development. These strategies enable companies to pool resources, share expertise, and leverage complementary strengths to enhance their competitive edge in a rapidly evolving landscape. Amid the search for innovative cancer therapies, antibody-drug conjugates have gained attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thereby minimizing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly engaging in strategic alliances to accelerate the development and commercialization of antibody-drug conjugates.

As the market becomes more competitive, companies seek to acquire or merge with other firms that have promising antibody-drug conjugate technologies or candidates in their pipelines. For instance, larger pharmaceutical companies acquire smaller biotech firms specializing in antibody-drug conjugate development to quickly incorporate advanced technologies into their existing product lines. Such acquisitions help the acquiring company enhance its portfolio and gain access to novel linker technologies, payloads, and targeting mechanisms that can improve the efficacy and safety profiles of its therapeutics. In October 2024, GlycoMimetics, Inc. entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the company plans to operate under the name Crescent Biopharma, Inc. In March 2024, Johnson & Johnson acquired Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform, to design and develop next-generation antibody-drug conjugates. In September 2024, Araris Biotech AG, a Swiss oncology and biotechnology company involved in developing next-generation antibody-drug conjugates, announced making an agreement with Innate Pharma. Under the agreement, Innate would assign Araris a portfolio of patents related to its transglutaminase conjugation technology.

The competitive landscape in the antibody-drug conjugates market is characterized by a high level of activity from key players engaging in strategic investments. This dynamism encourages innovation and improvement as companies strive to differentiate their products and establish leadership in the market. The influx of capital investment into oncology attracts new entrants, leading to a more vibrant ecosystem encouraging innovative ideas. Strategic investments through mergers, acquisitions, partnerships, and collaborations play a pivotal role in driving the growth of the antibody-drug conjugates market. These investments create a synergistic environment by enhancing product portfolios, improving manufacturing processes, and fostering innovation to propel the development of effective and targeted cancer therapies.

The comparative company analysis evaluates and categorizes the antibody drug conjugates market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Antibody Drug Conjugates Market. The key market players are ADC Therapeutics SA, Pfizer Inc, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Co Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, Takeda Pharmaceutical Co Ltd, Merck KGaA, Johnson & Johnson, Bristol-Myers Squibb Co, BioNTech SE, AbbVie Inc.

Based on technology, the antibody drug conjugates market is segmented into cleavable linker and non-cleavable linker. In 2023, the cleavable linker segment held the largest share of the market. Based on application, the antibody drug conjugates market is segmented into blood cancer, brain cancer, breast cancer, ovarian cancer, lung cancer and others. In 2023, the breast cancer segment held the largest share of the market.

Various organic and inorganic strategies are adopted by companies operating in the antibody drug conjugates market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the antibody drug conjugates market are listed below.

In November 2024, AstraZeneca constructed a US$ 1.5 billion manufacturing facility in Singapore dedicated to antibody drug conjugates (ADCs), which will improve the global supply of its ADC portfolio. ADCs are advanced treatments designed to deliver powerful cancer-fighting agents directly to cancer cells using targeted antibodies.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Antibody Drug Conjugates Market Landscape

  • 4.1 PEST Analysis
  • 4.2 Ecosystem Analysis
    • 4.2.1 List of Vendors in the Value Chain
    • 4.2.2 List of Approved Products
    • 4.2.3 Pipeline Analysis
    • 4.2.4 Regulatory Guidelines

5. Antibody Drug Conjugates Market - Key Market Dynamics

  • 5.1 Antibody Drug Conjugates Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Strategic Investments by Key Players
    • 5.2.2 Increase in Availability of Approved Products
  • 5.3 Market Restraints
    • 5.3.1 Manufacturing Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Expansion into New Indications
  • 5.5 Future Trends
    • 5.5.1 Expanding Clinical Trial Pipeline
  • 5.6 Impact of Drivers and Restraints:

6. Antibody Drug Conjugates Market - Global Market Analysis

  • 6.1 Antibody Drug Conjugates Market Revenue (US$ Million), 2021-2031
  • 6.2 Overview
  • 6.3 Antibody Drug Conjugates Market Forecast Analysis

7. Antibody Drug Conjugates Market Analysis - by Technology

  • 7.1 Cleavable Linker
    • 7.1.1 Overview
    • 7.1.2 Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Non-cleavable Linker
    • 7.2.1 Overview
    • 7.2.2 Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibody Drug Conjugates Market Analysis - by Application

  • 8.1 Blood Cancer
    • 8.1.1 Overview
    • 8.1.2 Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Brain Cancer
    • 8.2.1 Overview
    • 8.2.2 Brain Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Breast Cancer
    • 8.3.1 Overview
    • 8.3.2 Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Ovarian Cancer
    • 8.4.1 Overview
    • 8.4.2 Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Lung Cancer
    • 8.5.1 Overview
    • 8.5.2 Lung Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibody Drug Conjugates Market Analysis - by Target

  • 9.1 HER2
    • 9.1.1 Overview
    • 9.1.2 HER2: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 CD22
    • 9.2.1 Overview
    • 9.2.2 CD22: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 CD30
    • 9.3.1 Overview
    • 9.3.2 CD30: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibody Drug Conjugates Market Analysis - by Distribution Channel

  • 10.1 Retail Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Hospital Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibody Drug Conjugates Market - Geographical Analysis

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 North America Antibody Drug Conjugates Market Overview
    • 11.2.2 North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 North America: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.2.3.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.2.4 North America: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.2.4.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.2.5 North America: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.2.5.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.2.6 North America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.2.6.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.7 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.2 United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.2.1 United States: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.2.7.2.2 United States: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.2.7.2.3 United States: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.2.7.2.4 United States: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.2.7.3 Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.3.1 Canada: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.2.7.3.2 Canada: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.2.7.3.3 Canada: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.2.7.3.4 Canada: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.2.7.4 Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.4.1 Mexico: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.2.7.4.2 Mexico: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.2.7.4.3 Mexico: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.2.7.4.4 Mexico: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.3 Europe
    • 11.3.1 Europe Antibody Drug Conjugates Market Overview
    • 11.3.2 Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.3 Europe: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.3.3.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.3.4 Europe: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.3.4.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.3.5 Europe: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.3.5.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.3.6 Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.6.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.7 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.2 United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.2.1 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.2.2 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.2.3 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.2.4 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.3 Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.3.1 Germany: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.3.2 Germany: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.3.3 Germany: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.3.4 Germany: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.4 France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.4.1 France: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.4.2 France: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.4.3 France: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.4.4 France: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.5 Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.5.1 Italy: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.5.2 Italy: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.5.3 Italy: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.5.4 Italy: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.6 Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.6.1 Spain: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.6.2 Spain: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.6.3 Spain: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.6.4 Spain: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.7 Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.7.1 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.7.2 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.7.3 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.7.4 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific Antibody Drug Conjugates Market Overview
    • 11.4.2 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.4.3 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.4.3.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.4.4 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.4.4.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.4.5 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.4.5.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.4.6 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.6.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.7 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.2 China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.2.1 China: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.2.2 China: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.2.3 China: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.2.4 China: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.3 Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.3.1 Japan: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.3.2 Japan: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.3.3 Japan: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.3.4 Japan: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.4 India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.4.1 India: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.4.2 India: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.4.3 India: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.4.4 India: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.5 Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.5.1 Australia: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.5.2 Australia: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.5.3 Australia: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.5.4 Australia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.6 South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.6.1 South Korea: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.6.2 South Korea: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.6.3 South Korea: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.6.4 South Korea: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.7 Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.7.1 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.7.2 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.7.3 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.7.4 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.5 Middle East and Africa
    • 11.5.1 Middle East and Africa Antibody Drug Conjugates Market Overview
    • 11.5.2 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.5.3 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.5.3.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.5.4 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.5.4.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.5.5 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.5.5.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.5.6 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.6.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.7 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.2 South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.2.1 South Africa: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.2.2 South Africa: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.2.3 South Africa: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.2.4 South Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.7.3 Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.3.1 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.3.2 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.3.3 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.3.4 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.7.4 United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.4.1 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.4.2 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.4.3 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.4.4 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.7.5 Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.5.1 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.5.2 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.5.3 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.5.4 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.6 South and Central America
    • 11.6.1 South and Central America Antibody Drug Conjugates Market Overview
    • 11.6.2 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.6.3 South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.6.3.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.6.4 South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.6.4.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.6.5 South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.6.5.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.6.6 South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.6.6.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.6.7 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.2 Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.2.1 Brazil: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.6.7.2.2 Brazil: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.6.7.2.3 Brazil: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.6.7.2.4 Brazil: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.6.7.3 Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.3.1 Argentina: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.6.7.3.2 Argentina: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.6.7.3.3 Argentina: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.6.7.3.4 Argentina: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.6.7.4 Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.4.1 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.6.7.4.2 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.6.7.4.3 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.6.7.4.4 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel

12. Competitive Landscape

    • 12.1.1 Heat Map Analysis
    • 12.1.2 Company Share Analysis:

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Antibody Drug Conjugates Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 ADC Therapeutics SA
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 F. Hoffmann-La Roche Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Daiichi Sankyo Co Ltd
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Financial Overview
    • 14.4.4 SWOT Analysis
    • 14.4.5 Key Developments
  • 14.5 GSK Plc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Financial Overview
    • 14.5.4 SWOT Analysis
    • 14.5.5 Key Developments
  • 14.6 Gilead Sciences Inc
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 AstraZeneca Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Astellas Pharma Inc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 RemeGen Co Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Financial Overview
    • 14.9.4 SWOT Analysis
    • 14.9.5 Key Developments
  • 14.10 Takeda Pharmaceutical Co Ltd
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments
  • 14.11 Merck KGaA
    • 14.11.1 Key Facts
    • 14.11.2 Business Description
    • 14.11.3 Products and Services
    • 14.11.4 Financial Overview
    • 14.11.5 SWOT Analysis
    • 14.11.6 Key Developments
  • 14.12 Johnson & Johnson
    • 14.12.1 Key Facts
    • 14.12.2 Business Description
    • 14.12.3 Products and Services
    • 14.12.4 Financial Overview
    • 14.12.5 SWOT Analysis
    • 14.12.6 Key Developments
  • 14.13 Bristol-Myers Squibb Co
    • 14.13.1 Key Facts
    • 14.13.2 Business Description
    • 14.13.3 Products and Services
    • 14.13.4 Financial Overview
    • 14.13.5 SWOT Analysis
    • 14.13.6 Key Developments
  • 14.14 BioNTech SE
    • 14.14.1 Key Facts
    • 14.14.2 Business Description
    • 14.14.3 Products and Services
    • 14.14.4 Financial Overview
    • 14.14.5 SWOT Analysis
    • 14.14.6 Key Developments
  • 14.15 AbbVie Inc
    • 14.15.1 Key Facts
    • 14.15.2 Business Description
    • 14.15.3 Products and Services
    • 14.15.4 Financial Overview
    • 14.15.5 SWOT Analysis
    • 14.15.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. Antibody Drug Conjugates Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 4. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 5. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 6. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Target
  • Table 7. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 8. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 9. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 10. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 11. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 12. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 13. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 14. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 15. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 16. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 17. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 18. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 19. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 20. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 21. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 22. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 23. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 24. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 25. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 26. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 27. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 28. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 29. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 30. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 31. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 32. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 33. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 34. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 35. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 36. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 37. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 39. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 40. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 41. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 42. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 43. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 44. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 45. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 46. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 47. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 48. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 49. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 50. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 51. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 52. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 53. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 55. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 56. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 57. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 58. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 59. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 60. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 61. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 62. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 63. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 64. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 65. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 66. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 67. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 68. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 69. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 70. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 71. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 72. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 73. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 74. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 75. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 76. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 77. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 78. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 79. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 80. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 81. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 82. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 83. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 84. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 85. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 86. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 87. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 88. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 89. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 90. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 91. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 92. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 93. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 94. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 95. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 96. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 97. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 98. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 99. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 100. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 101. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 102. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 103. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 104. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 105. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 106. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 107. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 108. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 109. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 110. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 111. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 112. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 113. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 114. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 115. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 116. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 117. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 118. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 119. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 120. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 121. Company Share Analysis
  • Table 122. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
  • Table 123. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market

List Of Figures

  • Figure 1. Antibody Drug Conjugates Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Antibody Drug Conjugates Market Revenue (US$ Million), 2021-2031
  • Figure 5. Antibody Drug Conjugates Market Share (%) - by Technology (2023 and 2031)
  • Figure 6. Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Antibody Drug Conjugates Market Share (%) - by Application (2023 and 2031)
  • Figure 9. Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Brain Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Lung Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Antibody Drug Conjugates Market Share (%) - by Target (2023 and 2031)
  • Figure 16. HER2: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. CD22: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. CD30: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Antibody Drug Conjugates Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 21. Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Antibody Drug Conjugates Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 25. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. North America: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 27. North America: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 28. North America: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 29. North America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 30. North America: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 31. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Europe: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 36. Europe: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 37. Europe: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 38. Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 39. Europe: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 40. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 48. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 49. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 50. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 51. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 52. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 56. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 60. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 61. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 62. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 63. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 64. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 68. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 69. South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 70. South and Central America: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 71. South and Central America: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 72. South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 73. South and Central America: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 74. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 75. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 76. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 77. Growth Strategies in Antibody Drug Conjugates Market